Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women.
The aim of this study was to evaluate the effects of sibutramine on body composition and fat distribution, insulin resistance, and serum adiponectin levels in obese women. A total of 28 obese, premenopausal women (mean age, 34.5 +/- 13.7 years; BMI, 31.00 +/- 4.10 kg/m2) was studied before and after 12-week-course of sibutramine (10mg/day). Sibutramine treatment reduced body mass index (P < 0.05) and total body fat (P < 0.05). Abdominal subcutaneous and visceral fat areas (ASFA and AVFA) and mid-thigh low density muscle areas (LDMA) measured by computed-tomography decreased significantly (all, P < 0.05). Insulin resistance (IR) calculated from the homeostasis model assessment (HOMA) method decreased (P < 0.05) and serum adiponectin levels increased significantly (P < 0.05). In our sequential data, the changes of fasting serum insulin levels and the HOMA-IR scores, serum free fatty acids and triglyceride levels, serum adiponectin levels and the mid-thigh LDMA preceded significant changes of body weight, total body fat, and abdominal fat distribution, suggesting sibutramine might improve insulin sensitivity directly by alterations of fatty acid metabolism or secondarily by increasing serum adiponectin levels. Conclusively, sibutramine improved fat distribution and insulin resistance, and increased serum adiponectin levels in Korean obese nondiabetic premenopausal women.
Kim
D M
DM
Division of Endocrinology and Metabolism, Department of Internal Medicine, Yongdong Severance Hospital, College of Medicine, Yonsei University, 146-92 Dogok-Dong, Kangnam-Ku, Seoul, Republic of Korea.
Yoon
S J
SJ
Ahn
C W
CW
Cha
B S
BS
Lim
S K
SK
Kim
K R
KR
Lee
H C
HC
Huh
K B
KB
D052242:Adiponectin; D000273:Adipose Tissue / Q000033:anatomy & histology* / Q000187:drug effects; D000328:Adult; D001067:Appetite Depressants / Q000627:therapeutic use*; D015992:Body Mass Index; D003503:Cyclobutanes / Q000627:therapeutic use*; D006801:Humans; D007333:Insulin Resistance; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood*; D007723:Korea; D009765:Obesity / Q000188:drug therapy* / Q000503:physiopathology; D017697:Premenopause
D052242:Adiponectin; D001067:Appetite Depressants; D003503:Cyclobutanes; D036341:Intercellular Signaling Peptides and Proteins; C058254:sibutramine